News & Updates

Watch-and-wait approach feasible for therapy-responsive rectal cancer

Survival outcomes do not differ between patients with locally advanced rectal cancer treated with mandatory total mesorectal excision (TME) and those on selective watch-and-wait (WW) strategies following total neoadjuvant therapy (TNT), reports a study.

Watch-and-wait approach feasible for therapy-responsive rectal cancer

13 hours ago

Linaclotide improves bowel symptoms in children with functional constipation

16 May 2025 by

Treatment with linaclotide led to significantly improved symptoms of incomplete bowel evacuation and straining in paediatric patients aged 6–17 years with functional constipation, according to a phase III study presented at DDW 2025.

Linaclotide improves bowel symptoms in children with functional constipation

16 May 2025

ACE-I/ARB use helps avert death in cirrhosis patients

13 May 2025

Exposure to angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) may prevent mortality among patients with cirrhosis, a study has shown.

ACE-I/ARB use helps avert death in cirrhosis patients

13 May 2025

TAF prophylaxis prevents mother-to-child transmission of HBV

13 May 2025

Treatment with tenofovir alafenamide (TAF) is generally safe and effective for the prevention of hepatitis B virus (HBV) mother-to-child transmission (MTCT), reports a study, noting that the expected 8-week prenatal duration is feasible.

TAF prophylaxis prevents mother-to-child transmission of HBV

13 May 2025

IBD patients who undergo coronary intervention at increased risk of MACE

08 May 2025

Patients with inflammatory bowel disease (IBD) have a higher likelihood of experiencing major adverse cardiovascular events (MACE) after coronary interventions, according to a study.

IBD patients who undergo coronary intervention at increased risk of MACE

08 May 2025

Which agents improve histology in EoE?

05 May 2025

Several medications such as orodispersible budesonide (ODB), oral viscous budesonide (OVB), and fluticasone, among others, demonstrate efficacy in the treatment of eosinophilic esophagitis (EoE) in adults and children, according to the results of a network meta-analysis.

Which agents improve histology in EoE?

05 May 2025

Anxiety, depression predict pain, HRQoL in cirrhosis patients

03 May 2025

Pain is prevalent among patients with cirrhosis who are undergoing liver transplant evaluation, a study has found. Anxiety and depression show a significant association with pain and appear to predict poor health-related quality of life (HRQoL) in this population.

Anxiety, depression predict pain, HRQoL in cirrhosis patients

03 May 2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-April-2025

02 May 2025

New drug applications approved by US FDA as of 1-15 April 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-April-2025

02 May 2025

Progestin-only contraceptives may pose NAFLD risk among women with GDM history

25 Apr 2025 by

The use of progestin-only contraceptives may put women with a history of gestational diabetes mellitus (GDM) at risk of nonalcoholic fatty liver disease (NAFLD), as shown in a small prospective study.

Progestin-only contraceptives may pose NAFLD risk among women with GDM history

25 Apr 2025

Atezolizumab + trastuzumab + XELOX: A promising combination in advanced gastric cancer

20 Apr 2025

Adding atezolizumab to the combination of trastuzumab plus capecitabine and oxaliplatin chemotherapy (XELOX) helps improve treatment response in patients with ERBB2-positive locally advanced resectable gastric cancer (GC) and gastroesophageal junction (GEJ) adenocarcinoma, according to the results of the open-label phase II trial conducted in China.

Atezolizumab + trastuzumab + XELOX: A promising combination in advanced gastric cancer

20 Apr 2025

News & Updates

Filter by Specialty:

Specialty:

Watch-and-wait approach feasible for therapy-responsive rectal cancer

Watch-and-wait approach feasible for therapy-responsive rectal cancer

Linaclotide improves bowel symptoms in children with functional constipation

Linaclotide improves bowel symptoms in children with functional constipation

ACE-I/ARB use helps avert death in cirrhosis patients

ACE-I/ARB use helps avert death in cirrhosis patients

TAF prophylaxis prevents mother-to-child transmission of HBV

TAF prophylaxis prevents mother-to-child transmission of HBV

IBD patients who undergo coronary intervention at increased risk of MACE

IBD patients who undergo coronary intervention at increased risk of MACE

Which agents improve histology in EoE?

Which agents improve histology in EoE?

Anxiety, depression predict pain, HRQoL in cirrhosis patients

Anxiety, depression predict pain, HRQoL in cirrhosis patients

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-April-2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-April-2025

Progestin-only contraceptives may pose NAFLD risk among women with GDM history

Progestin-only contraceptives may pose NAFLD risk among women with GDM history

Atezolizumab + trastuzumab + XELOX: A promising combination in advanced gastric cancer

Atezolizumab + trastuzumab + XELOX: A promising combination in advanced gastric cancer